Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of combining bortezomib with paclitaxel in treating
patients who have advanced or metastatic solid tumors. Bortezomib may stop the growth of
cancer cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy
work in different ways to stop tumor cells from dividing so they stop growing or die.
Combining bortezomib with paclitaxel may kill more tumor cells.